# Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

> **NCT01297270** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 658 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** BI201335
- **DRUG:** PegIFN/RBV
- **DRUG:** BI201335
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01297270
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 658 (ACTUAL)
- **Last updated:** 2015-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01297270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01297270, "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01297270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*